StockData
X4 Pharmaceuticals, Inc logo

X4 Pharmaceuticals, Inc (XFOR) stock

XFORNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 3/30
$3.09+0.26 (+9.19%)

Close on Nov 17, 2026Market cap $306.36MP/E –Yield –

X4 Pharmaceuticals r&d expenses

Research and development expenses are spending on new products and technology.

X4 Pharmaceuticals's R&D Expenses for the twelve months ending Sep 30, 2026 was $62.39M, down 17.8% year over year. For fiscal 2025 it was $72.72M, down 10.9% from the year before. The highest annual figure on record is $81.64M in fiscal 2024.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$72.72M-10.9%
FY2024Dec 31, 2024$81.64M+13.4%
FY2023Dec 31, 2023$72.02M+17.9%
FY2022Dec 31, 2022$61.06M+20.6%
FY2021Dec 31, 2021$50.65M+20.8%
FY2020Dec 31, 2020$41.93M+39.0%
FY2019Dec 31, 2019$30.16M+48.3%
FY2018Dec 31, 2018$20.35M+19.2%
FY2017Dec 31, 2017$17.07M-4.3%
FY2016Dec 31, 2016$17.83M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026$13.34M-23.0%
Q2 FY2026Jun 30, 2026$15.08M-17.8%
Q1 FY2026Mar 31, 2026$15.45M-16.5%
Q4 FY2025Dec 31, 2025$18.52M-14.7%
Q3 FY2025Sep 30, 2025$17.34M-9.6%
Q2 FY2025Jun 30, 2025$18.35M-12.3%
Q1 FY2025Mar 31, 2025$18.51M-6.8%
Q4 FY2024Dec 31, 2024$21.70M+39.1%
Q3 FY2024Sep 30, 2024$19.17M-13.1%
Q2 FY2024Jun 30, 2024$20.91M+10.0%
Q1 FY2024Mar 31, 2024$19.85M+40.7%
Q2 FY2023Jun 30, 2023$15.60M+12.9%
Q1 FY2023Mar 31, 2023$22.06M+56.3%
Q4 FY2022Dec 31, 2022$19.01M+56.3%
Q3 FY2022Sep 30, 2022$14.11M+7.0%
Q2 FY2022Jun 30, 2022$13.82M+4.8%
Q1 FY2022Mar 31, 2022$14.11M+16.6%
Q4 FY2021Dec 31, 2021$12.16M-1.1%
Q3 FY2021Sep 30, 2021$13.19M+15.9%
Q2 FY2021Jun 30, 2021$13.19M+41.2%
Q1 FY2021Mar 31, 2021$12.10M+35.8%
Q4 FY2020Dec 31, 2020$12.30M+74.1%
Q3 FY2020Sep 30, 2020$11.38M+32.5%
Q2 FY2020Jun 30, 2020$9.34M+5.5%
Q1 FY2020Mar 31, 2020$8.91M+57.6%
Q4 FY2019Dec 31, 2019$7.07M+50.7%
Q3 FY2019Sep 30, 2019$8.59M+39.5%
Q2 FY2019Jun 30, 2019$8.85M+86.2%
Q1 FY2019Mar 31, 2019$5.66M+19.2%
Q4 FY2018Dec 31, 2018$4.69M-49.2%
Q3 FY2018Sep 30, 2018$6.16M-41.9%
Q2 FY2018Jun 30, 2018$4.76M+21.7%
Q1 FY2018Mar 31, 2018$4.74M+8.0%
Q4 FY2017Dec 31, 2017$9.23M–
Q3 FY2017Sep 30, 2017$10.60M–
Q2 FY2017Jun 30, 2017$3.91M–
Q1 FY2017Mar 31, 2017$4.39M–

More X4 Pharmaceuticals figures

See a number that looks wrong?